According to the latest experimental studies, heath physicists have encountered safe methods to use
According to the latest experimental studies, heath physicists have encountered safe methods to use a radioactive protein found in scorpion venom to treat thyroid cancer. The venom of a yellow species of scorpions found in Israel is promising to develop into a revolutionary technique to fight different types of tissues affected by cancer.
The Transmolecular Corporation in Cambridge has successfully obtained in the laboratory a radioactive variant of the venom protein. The new substance is called TM-601 and consists of the radioactive substance Iodine-131 and an artificially obtained venom protein. When the artificial compound is released into the blood, the radioactive waves kill the foreign, cancer cells.
Every year, about 17000 persons suffer from this type of cancer and many of them die within the first months of treatment. The new technique promises a remission of the cancer within the first months, after the radioactive compound has been injected into the body. The patient will require no further chemotherapy or traditional therapeutically radiations. The procedure promises a good improvement of the cancer symptoms and a high rate of surviving.
The phase two of the human trial using the new compound shows safe ways of handling the new treatment, even by injecting higher doses of radiations into the cells than during the first stage experiments.
The physicians duty is to release on the medical market a both safe and legal product with a high index of success. The doctors prescribing this therapy must also protect the family members and the environment of the patient from the radioactivity of the drug.
During the human testing, a group of several patients receive the medication three times within three weeks, while another group gets the therapy six times in six weeks. All patients receive the same quantity of medicine, meaning 200 MCI in the treatment of thyroid cancer. The results are satisfactory compared to other types of therapy used before.
Research scientists discovered that TM-601 is not being assimilated by other tissues besides the cancer cells. The tissue parts near the tumor also receive an amount of radiation but in a lower rate. Before the treatment, patients are administered with high doses of non-radioactive iodine to prevent the assimilation of the drug by the absorbing thyroid, to block the uptake of Iodine-131. The thyroid gland quickly absorbs iodine in normal circumstances.
A part of the radiations received during the treatment are transmitted by the patients body to the family members in the first hours after returning from the hospital. However, studies show that the level of radioactive waves spread by the body is not larger than the ones reflected after traditional radioactive therapy.
The Transmolecular Corporation in Cambridge has successfully obtained in the laboratory a radioactive variant of the venom protein. The new substance is called TM-601 and consists of the radioactive substance Iodine-131 and an artificially obtained venom protein. When the artificial compound is released into the blood, the radioactive waves kill the foreign, cancer cells.
Every year, about 17000 persons suffer from this type of cancer and many of them die within the first months of treatment. The new technique promises a remission of the cancer within the first months, after the radioactive compound has been injected into the body. The patient will require no further chemotherapy or traditional therapeutically radiations. The procedure promises a good improvement of the cancer symptoms and a high rate of surviving.
The phase two of the human trial using the new compound shows safe ways of handling the new treatment, even by injecting higher doses of radiations into the cells than during the first stage experiments.
The physicians duty is to release on the medical market a both safe and legal product with a high index of success. The doctors prescribing this therapy must also protect the family members and the environment of the patient from the radioactivity of the drug.
During the human testing, a group of several patients receive the medication three times within three weeks, while another group gets the therapy six times in six weeks. All patients receive the same quantity of medicine, meaning 200 MCI in the treatment of thyroid cancer. The results are satisfactory compared to other types of therapy used before.
Research scientists discovered that TM-601 is not being assimilated by other tissues besides the cancer cells. The tissue parts near the tumor also receive an amount of radiation but in a lower rate. Before the treatment, patients are administered with high doses of non-radioactive iodine to prevent the assimilation of the drug by the absorbing thyroid, to block the uptake of Iodine-131. The thyroid gland quickly absorbs iodine in normal circumstances.
A part of the radiations received during the treatment are transmitted by the patients body to the family members in the first hours after returning from the hospital. However, studies show that the level of radioactive waves spread by the body is not larger than the ones reflected after traditional radioactive therapy.
